{"id":"NCT05072080","sponsor":"Bavarian Nordic","briefTitle":"A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)","officialTitle":"A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-29","primaryCompletion":"2023-04-03","completion":"2023-04-03","firstPosted":"2021-10-08","resultsPosted":"2024-08-30","lastUpdate":"2024-08-30"},"enrollment":3258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Chikungunya Virus"],"interventions":[{"type":"BIOLOGICAL","name":"CHIKV VLP/adjuvant","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.","primaryOutcome":{"measure":"Incidence of Solicited Adverse Events (AE)","timeFrame":"7 days post-vaccination","effectByArm":[{"arm":"Group 1","deltaMin":319,"sd":null},{"arm":"Group 2","deltaMin":373,"sd":null},{"arm":"Group 3","deltaMin":366,"sd":null},{"arm":"Group 4","deltaMin":124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":47,"countries":["United States"]},"refs":{"pmids":["40158526","39004524","35709798"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":918},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","Arthralgia"]}}